VYTRUS BIOTECH EO -01 - Asset Resilience Ratio

Latest as of December 2025: 0.00%

VYTRUS BIOTECH EO -01 (V5P) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€600.00
≈ $701.46 USD Cash + Short-term Investments

Total Assets

€14.66 Million
≈ $17.14 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how VYTRUS BIOTECH EO -01's Asset Resilience Ratio has changed over time. See V5P FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down VYTRUS BIOTECH EO -01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of VYTRUS BIOTECH EO -01.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €600.00 0.0%
Total Liquid Assets €600.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: VYTRUS BIOTECH EO -01 maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

VYTRUS BIOTECH EO -01 Industry Peers by Asset Resilience Ratio

Compare VYTRUS BIOTECH EO -01's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 5.66%
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Abivax SA
PA:ABVX
Biotechnology 2.34%
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
Biotechnology 5.07%
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Biotechnology 43.36%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
REMEGEN CO. LTD YC 1
F:REG
Biotechnology 16.77%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Annual Asset Resilience Ratio for VYTRUS BIOTECH EO -01 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for VYTRUS BIOTECH EO -01.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% €600.00
≈ $701.46
€14.66 Million
≈ $17.14 Million
0.00pp
2024-12-31 0.01% €600.00
≈ $701.46
€11.13 Million
≈ $13.01 Million
0.00pp
2023-12-31 0.01% €600.00
≈ $701.46
€9.31 Million
≈ $10.89 Million
0.00pp
2021-12-31 0.01% €522.14
≈ $610.44
€7.18 Million
≈ $8.40 Million
--
pp = percentage points

About VYTRUS BIOTECH EO -01

F:V5P Germany Biotechnology
Market Cap
$148.51 Million
€127.03 Million EUR
Market Cap Rank
#18122 Global
#1695 in Germany
Share Price
€16.90
Change (1 day)
+3.36%
52-Week Range
€4.80 - €21.60
All Time High
€21.60
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more